Senior Manager, Epidemiology/Real-World Data and Analytics (Oncology)
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Senior Manager, Epidemiology for our Health Economics and Outcomes Research team to support our Oncology programs. In this role, you will generate real-world evidence that influences the development and commercialization of innovative oncology therapies while collaborating with HEOR colleagues and key collaborators.
Job description
When & where
- Location: Sleepy Hollow, NY
- Work model/flexibility: On-site 4 days/week
Discover your role
- Generate high-quality observational research using diverse real-world data sources to support development and commercial strategies
- Evaluate and implement emerging design and analytic methods to strengthen our RWE capabilities
- Synthesize and critically assess scientific evidence for regulatory and payor submissions, press releases, and internal business needs
- Support global HTA and payor submissions with epidemiology and RWE inputs for value dossiers and reimbursement packages
- Provide technical expertise to clinical development and evidence generation, and external control arms and hybrid approaches
- Stay current with evolving regulatory and payor expectations for RWE and guide internal teams on the implications
- Participate in epidemiologic design discussions in a peer review forum
- Drive projects forward with a growth mindset, proactively identifying solutions and managing priorities
This role requires
- Doctoral degree in epidemiology or a related subject area (e.g., health services research, public health), plus at least 2 years of experience across academia, pharma/biotech, or consulting
- Hands-on experience drafting technical design documents, study protocols and/or statistical analysis plans using real-world data, with a record of peer-reviewed publications
- Excellent communication skills, with the ability to translate complex designs and findings into clear, actionable insights for diverse audiences
- Experience conducting epidemiology and RWE research in oncology, including familiarity with cancer treatment paradigms and oncology endpoints is preferred
- Experience applying advanced analytical methods to large healthcare datasets, including causal inference, bias assessment, and robust estimation is preferred
- Familiarity with global HTA and payor evidence needs, value and reimbursement strategies are preferred
Requirements
- Doctoral degree in epidemiology or a related subject area (e.g., health services research, public health)
- At least 2 years of experience across academia, pharma/biotech, or consulting
- Hands-on experience drafting technical design documents, study protocols and/or statistical analysis plans using real-world data
- Record of peer-reviewed publications
- Excellent communication skills, with the ability to translate complex designs and findings into clear, actionable insights for diverse audiences
- Experience conducting epidemiology and RWE research in oncology, including familiarity with cancer treatment paradigms and oncology endpoints is preferred
- Experience applying advanced analytical methods to large healthcare datasets, including causal inference, bias assessment, and robust estimation is preferred
- Familiarity with global HTA and payor evidence needs, value and reimbursement strategies are preferred
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.